{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T21:22:48Z","timestamp":1781904168658,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T00:00:00Z","timestamp":1506643200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00393-017-0335-z","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T20:22:07Z","timestamp":1506716527000},"page":"33-37","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Monoklonale Gammopathie unklarer Signifikanz und multiples Myelom","Monoclonal gammopathy of undetermined significance and multiple myeloma"],"prefix":"10.1007","volume":"76","author":[{"given":"M.","family":"Schmalzing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-P.","family":"Tony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,29]]},"reference":[{"key":"335_CR1","volume-title":"Monoklonale Gammopathie unklarer Signifikanz. Leitlinie. Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie h\u00e4matologischer und onkologischer Erkrankungen","author":"M Kort\u00fcm","year":"2010","unstructured":"Kort\u00fcm M, Einsele H, Naumann R, Peest D, Liebisch P, Goldschmidt H (2010) Monoklonale Gammopathie unklarer Signifikanz. Leitlinie. Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie h\u00e4matologischer und onkologischer Erkrankungen. www.onkopedia.de . Zugegriffen: 22.06.2017"},{"key":"335_CR2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International Myeloma Working Group","year":"2003","unstructured":"International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma. Br J Haematol 121:749\u2013757","journal-title":"Br J Haematol"},{"issue":"5","key":"335_CR3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"MV Mateos","year":"2013","unstructured":"Mateos MV, Hern\u00e1ndez MT, Giraldo P et al (2013) Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N\u00a0Engl J Med 369(5):438\u2013447","journal-title":"N Engl J Med"},{"issue":"12","key":"335_CR4","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et\u00a0al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013e548","journal-title":"Lancet Oncol"},{"issue":"6","key":"335_CR5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/art.1780120604","volume":"12","author":"GJ Goldenberg","year":"1969","unstructured":"Goldenberg GJ, Paraskevas F, Israels LG (1969) The association of rheumatoid arthritis with plasma cell neoplasm. Arthritis Rheum 12(6):569\u2013579","journal-title":"Arthritis Rheum"},{"issue":"6","key":"335_CR6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1177\/0961203307079045","volume":"16","author":"YM Ali","year":"2007","unstructured":"Ali YM, Urowitz MB, Ibanez D, Gladman DD (2007) Monoclonal gammopathy in systemic lupus erythematosus. Lupus 16(6):426\u2013429","journal-title":"Lupus"},{"issue":"5","key":"335_CR7","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/art.39534.","volume":"68","author":"AL Tomi","year":"2016","unstructured":"Tomi AL, Belkhir R, Nocturne G, Desmoulins F, Berge E, Pavy S, Miceli-Richard C, Mariette X, Seror R (2016) Brief report: Monoclonal Gammopathy and risk of Lymphoma and multiple myeloma in patients with primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol 68(5):1245\u20131250. doi: 10.1002\/art.39534","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"335_CR8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1158\/1055-9965.EPI-13-0695","volume":"23","author":"CM McShane","year":"2014","unstructured":"McShane CM, Murray LJ, Landgren O, O\u2019Rorke MA, Korde N, Kunzmann AT, Ismail MR, Anderson LA (2014) Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a\u00a0systematic review. Cancer Epidemiol Biomarkers Prev 23(2):332\u2013342","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"335_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2859-8","author":"EK Lindqvist","year":"2016","unstructured":"Lindqvist EK, Landgren O, Lund SH, Turesson I, Hultcrantz M, Goldin L, Bj\u00f6rkholm M, Kristinsson SY (2016) History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a\u00a0population-based study. Ann Hematol. doi: 10.1007\/s00277-016-2859-8","journal-title":"Ann Hematol"},{"issue":"5","key":"335_CR10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0145-2126(02)00082-6","volume":"27","author":"T Waddelow","year":"2003","unstructured":"Waddelow T, Kantarjian HM, Albitar M, Giles FJ (2003) Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. Leuk Res 27(5):375\u2013380","journal-title":"Leuk Res"},{"issue":"11","key":"335_CR11","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1111\/j.1468-3083.2011.04216.x.","volume":"26","author":"F Prignano","year":"2012","unstructured":"Prignano F, Pescitelli L, Ricceri F, Ermini A, Lotti T (2012) Development of MGUS in psoriatic patients: a\u00a0possible undiagnosed event during anti-TNF-\u03b1-treatment. J\u00a0Eur Acad Dermatol Venereol 26(11):1444\u20131448. doi: 10.1111\/j.1468-3083.2011.04216.x","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 1","key":"335_CR12","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1002\/ddr.21191.","volume":"75","author":"A Conti","year":"2014","unstructured":"Conti A, Esposito I, Lasagni C, Miglietta R, Padalino C, Fabiano A, Pellacani G (2014) Monoclonal gammopathy of undetermined significance in patients with psoriasis: is it really a\u00a0side effect of biological therapy? Drug Dev Res 75(Suppl 1):S35\u2013S37. doi: 10.1002\/ddr.21191","journal-title":"Drug Dev Res"},{"issue":"11","key":"335_CR13","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1111\/jdv.12565.","volume":"29","author":"V Lernia Di","year":"2015","unstructured":"Di Lernia V, Ficarelli E, Lallas A, Possemato N, Chiarolanza I, Salvarani C (2015) Frequency of monoclonal gammopathy in psoriatic patients receiving anti-TNF therapy compared with patients taking conventional drugs: a\u00a0cross-sectional study. J\u00a0Eur Acad Dermatol Venereol 29(11):2262\u20132263. doi: 10.1111\/jdv.12565","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl2","key":"335_CR14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/annrheumdis-2015-eular.3993","volume":"74","author":"C Salliot","year":"2015","unstructured":"Salliot C, Beaudoin C, Chauffier K et\u00a0al (2015) Prevalence and evolution of Monoclonal Gammopathy of undetermined significance in patients with rheumatoid arthritis treated with Aabatacept: data from the ORA registry. Ann Rheum Dis 74(Suppl2):445","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"335_CR15","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.autrev.2014.08.031","volume":"13","author":"A N\u00e9el","year":"2014","unstructured":"N\u00e9el A, Henry B, Barbarot S, Masseau A, Perrin F, Bernier C, Kyndt X, Puechal X, Weiller PJ, Decaux O, Ninet J, Hot A, Aouba A, Astudillo L, Berthelot JM, Bonnet F, Brisseau JM, Cador B, Closs-Prophette F, Dejoie T, de Korwin JD, Dhote R, Fior R, Grosbois B, Hachulla E, Hatron PY, Jardel H, Launay D, Lorleac\u2019h A, Pottier P, Moulis G, Serratrice J, Smail A, Hamidou M (2014) Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler\u2019s syndrome: a\u00a0French multicenter study. Autoimmun Rev 13(10):1035\u20131041. doi: 10.1016\/j.autrev.2014.08.031","journal-title":"Autoimmun Rev"},{"issue":"3","key":"335_CR16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semarthrit.2007.04.001","volume":"37","author":"HD Koning de","year":"2007","unstructured":"de Koning HD, Bodar EJ, van der Meer JW, Simon A (2007) Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 37(3):137","journal-title":"Semin Arthritis Rheum"},{"key":"335_CR17","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2169\/internalmedicine.50.4636","volume":"50","author":"Y Matsuyama","year":"2011","unstructured":"Matsuyama Y, Nagashima T et al (2011) Successful treatment of a\u00a0patient with rheumatoid arthritis and IgA-kappa multiple myeloma with Tocilizumab. Intern Med 50:639\u2013642","journal-title":"Intern Med"},{"key":"335_CR18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1365-2141.2008.07024.x","volume":"141","author":"P Kapoor","year":"2008","unstructured":"Kapoor P, Greipp PT, Morice WG, Rajkumar SV, Witzig TE, Greipp PR (2008) Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol 141:135\u2013148","journal-title":"Br. J. Haematol."},{"issue":"5","key":"335_CR19","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A et\u00a0al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516\u20132520","journal-title":"Blood"},{"key":"335_CR20","doi-asserted-by":"publisher","unstructured":"Richardson PG, Hungria VT, Yoon SS et\u00a0al (2016) Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood 127(6):713\u2013721. doi: 10.1182\/blood-2016-05-717777","DOI":"10.1182\/blood-2016-05-717777"},{"issue":"9","key":"335_CR21","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/ajh.24392","volume":"91","author":"V Rajkumar","year":"2016","unstructured":"Rajkumar V (2016) Myeloma today: disease definitions and treatment advances. Am J Hematol 91(9):965","journal-title":"Am J Hematol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-017-0335-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-017-0335-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-017-0335-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T23:23:50Z","timestamp":1750893830000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-017-0335-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,29]]},"references-count":21,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["335"],"URL":"https:\/\/doi.org\/10.1007\/s00393-017-0335-z","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,29]]}}}